Format and content of regulatory dossiers for drugs, devices, biologicals, herbals and nutraceuticals MCQs With Answer

Introduction: This quiz set explores the format and content of regulatory dossiers for drugs, medical devices, biologicals, herbals and nutraceuticals relevant to M.Pharm students preparing for Indian and international regulatory submissions. Questions emphasize the Common Technical Document (CTD/eCTD) structure, Module-specific expectations (CMC, nonclinical, clinical), master files (DMF/ASMF), and dossier requirements specific to devices, biologics, traditional/herbal products and nutraceuticals. Included are aspects of stability, GMP, quality attributes, risk management, clinical and nonclinical evidence, pharmacovigilance and pertinent Indian regulatory nuances (CDSCO, FSSAI, AYUSH). This set targets applied knowledge needed to prepare, review or audit regulatory dossiers for marketing authorisation and post‑marketing compliance.

Q1. Which module of the CTD/eCTD primarily contains detailed Chemistry, Manufacturing and Controls (CMC) information for a small molecule drug product?

• Module 1 — Administrative and prescribing information
• Module 2 — Quality overall summaries
• Module 3 — Quality (CMC) data
• Module 5 — Clinical study reports

Correct Answer: Module 3 — Quality (CMC) data

Q2. In an eCTD submission, Module 1 content is considered regional. Which of the following is typically included in Module 1?

• Detailed stability data and specifications
• Clinical study reports and investigator brochures
• Regional application forms, labeling, and local administrative documents
• Nonclinical study reports (toxicology)

Correct Answer: Regional application forms, labeling, and local administrative documents

Q3. A Drug Master File (DMF) is primarily used to:

• Provide clinical trial data for regulatory review
• Submit marketing authorization application for the finished product
• Allow a supplier to confidentially submit detailed information about an active substance or excipient to regulators
• Replace batch release test records at the manufacturer

Correct Answer: Allow a supplier to confidentially submit detailed information about an active substance or excipient to regulators

Q4. For biosimilar regulatory dossiers, which element is most critical to demonstrate similarity to the reference biologic?

• Identical excipient list in the finished product
• Comprehensive analytical comparability, including primary structure, post‑translational modifications and functional assays
• Use of the same manufacturing site as the reference product
• Longer clinical trials than originator biologic

Correct Answer: Comprehensive analytical comparability, including primary structure, post‑translational modifications and functional assays

Q5. Which standard is commonly referenced for biological evaluation of medical device materials included in a device dossier?

• ISO 13485 — Quality management systems for medical devices
• ISO 10993 — Biological evaluation of medical devices (biocompatibility)
• GMP Annex 1 — Sterile medicinal products
• ICH Q3A — Impurities in new drug substances

Correct Answer: ISO 10993 — Biological evaluation of medical devices (biocompatibility)

Q6. In a pharmaceutical quality dossier, which document contains the stability protocol, summary and proposed shelf life and storage conditions?

• Drug Master File (DMF)
• Stability section in Module 3 (CMC)
• Clinical study reports (Module 5)
• Pharmacovigilance system master file

Correct Answer: Stability section in Module 3 (CMC)

Q7. For herbal drug dossiers under AYUSH or regulatory pathways, which of the following is a typical required element?

• Comprehensive randomized clinical trials for every traditional claim regardless of history
• Pharmacognostical identification, standardization, marker compounds and traditional use documentation
• Only a Certificate of Pharmaceutical Product is needed
• Detailed viral safety data as for biologics

Correct Answer: Pharmacognostical identification, standardization, marker compounds and traditional use documentation

Q8. Which ICH guideline series primarily addresses quality aspects such as impurity qualification and stability testing?

• ICH E series
• ICH Q series
• ICH M series
• ICH S series

Correct Answer: ICH Q series

Q9. For nutraceuticals and functional foods in India, which regulator and document framework governs ingredient approval and claims?

• CDSCO — Schedule Y
• FSSAI — Food Safety and Standards regulations and health claim substantiation
• AYUSH — Traditional Medicine rules
• WHO GMP guidelines

Correct Answer: FSSAI — Food Safety and Standards regulations and health claim substantiation

Q10. A Risk Management Plan (RMP) in a dossier is primarily intended to:

• Document manufacturing batch records
• Present preclinical pharmacology data only
• Describe identified and potential safety concerns and measures to minimize risks during post‑marketing
• Replace periodic safety update reports (PSURs)

Correct Answer: Describe identified and potential safety concerns and measures to minimize risks during post‑marketing

Q11. Which section of a device technical dossier presents design verification and validation evidence?

• Device description and specification
• Design and manufacturing information including design verification and validation reports
• Clinical evaluation report only
• Labeling and instructions for use

Correct Answer: Design and manufacturing information including design verification and validation reports

Q12. For an eCTD submission, Module 2 contains overviews and summaries. Which of the following is a core element of Module 2?

• Raw analytical chromatograms for impurity identification
• Quality overall summary (QOS), nonclinical overview and clinical overview with summaries
• Regional application form and labeling
• Batch release certificates

Correct Answer: Quality overall summary (QOS), nonclinical overview and clinical overview with summaries

Q13. A Certificate of Pharmaceutical Product (CPP) included in some export dossiers primarily confirms:

• The product passed all stability studies in the importing country
• The product is authorised for sale in the issuing country and complies with GMP
• The manufacturing site holds ISO 14001 certification
• Bioequivalence studies are not required

Correct Answer: The product is authorised for sale in the issuing country and complies with GMP

Q14. Which document is used to provide confidential manufacturing information about an active pharmaceutical ingredient to a regulatory authority without disclosing it to the applicant?

• Module 1 administrative dossier
• Active Substance Master File (ASMF) / DMF
• Clinical study protocol
• Pharmacovigilance database extract

Correct Answer: Active Substance Master File (ASMF) / DMF

Q15. For biologicals such as vaccines, which dossier element is essential to demonstrate viral safety of the product?

• Stability at high temperature only
• Process validation and viral clearance/ inactivation data plus source material testing
• Device biocompatibility reports
• Only clinical immunogenicity data without process details

Correct Answer: Process validation and viral clearance/ inactivation data plus source material testing

Q16. For a generic small‑molecule drug in India, a waiver of bioequivalence studies can sometimes be granted when:

• The product is a new chemical entity
• The formulation is injectable and sterile only
• The drug is a topical product where systemic absorption is negligible and regulatory guidance permits waivers
• There is no reference product in any market

Correct Answer: The drug is a topical product where systemic absorption is negligible and regulatory guidance permits waivers

Q17. In a nutraceutical dossier, substantiation of a health claim typically requires:

• Only historical traditional use statements
• Robust scientific evidence including human intervention studies or systematic reviews appropriate to the claim
• No evidence if the ingredient is plant‑derived
• Only in vitro antioxidant assays

Correct Answer: Robust scientific evidence including human intervention studies or systematic reviews appropriate to the claim

Q18. Which of the following is a primary objective of the CMC section within a dossier for a biological product?

• Show tolerability data in elderly subjects only
• Characterize product quality attributes, manufacturing process controls and batch consistency
• List marketing strategies
• Describe patient support programs

Correct Answer: Characterize product quality attributes, manufacturing process controls and batch consistency

Q19. Which post‑marketing document summarises worldwide safety data periodically and is often required in regulatory dossiers?

• Biocompatibility assessment
• Periodic Safety Update Report (PSUR) / Periodic Benefit‑Risk Evaluation Report (PBRER)
• Design history file
• Certificate of analysis for each batch

Correct Answer: Periodic Safety Update Report (PSUR) / Periodic Benefit‑Risk Evaluation Report (PBRER)

Q20. For medical devices in India, a technical dossier should include risk analysis. Which standard is typically cited for risk management methodology?

• ISO 9001
• ISO 14971 — Application of risk management to medical devices
• ICH E6 (GCP)
• Ph. Eur. monographs

Correct Answer: ISO 14971 — Application of risk management to medical devices

Download